PT  - JOURNAL ARTICLE
AU  - Chunyin Gu
AU  - Xiaodan Cao
AU  - Zongda Wang
AU  - Xue Hu
AU  - Yanfeng Yao
AU  - Yiwu Zhou
AU  - Peipei Liu
AU  - Xiaowu Liu
AU  - Ge Gao
AU  - Xiao Hu
AU  - Yecheng Zhang
AU  - Zhen Chen
AU  - Li Gao
AU  - Yun Peng
AU  - Fangfang Jia
AU  - Chao Shan
AU  - Li Yu
AU  - Kunpeng Liu
AU  - Nan Li
AU  - Weiwei Guo
AU  - Guoping Jiang
AU  - Juan Min
AU  - Jianjian Zhang
AU  - Lu Yang
AU  - Meng Shi
AU  - Tianquan Hou
AU  - Yanan Li
AU  - Weichen Liang
AU  - Guoqiao Lu
AU  - Congyi Yang
AU  - Yuting Wang
AU  - Kaiwen Xia
AU  - Zheng Xiao
AU  - Jianhua Xue
AU  - Xueyi Huang
AU  - Xin Chen
AU  - Haixia Ma
AU  - Donglin Song
AU  - Zhongzong Pan
AU  - Xueping Wang
AU  - Haibing Guo
AU  - Hong Liang
AU  - Zhiming Yuan
AU  - Wuxiang Guan
AU  - Su-Jun Deng
TI  - A human antibody with blocking activity to RBD proteins of multiple SARS-CoV-2 variants including B.1.351 showed potent prophylactic and therapeutic efficacy against SARS-CoV-2 in rhesus macaques
AID  - 10.1101/2021.02.07.429299
DP  - 2021 Jan 01
TA  - bioRxiv
PG  - 2021.02.07.429299
4099  - http://biorxiv.org/content/early/2021/02/08/2021.02.07.429299.short
4100  - http://biorxiv.org/content/early/2021/02/08/2021.02.07.429299.full
AB  - Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), which causes coronavirus disease-2019 (COVID-19), interacts with the host cell receptor angiotensin-converting enzyme 2 (hACE2) via its spike 1 protein for infection. After the virus sequence was published, we identified two potent antibodies against SARS-CoV-2 RBD from antibody libraries using a phage-to-yeast (PtY) display platform in only 10 days. Our lead antibody JMB2002, now in a phase I clinical trial, showed broad-spectrum in vitro blocking activity against hACE2 binding to the RBD of multiple SARS-CoV-2 variants including B.1.351 that was reportedly much more resistant to neutralization by convalescent plasma, vaccine sera and some clinical stage neutralizing antibodies. Furthermore, JMB2002 has demonstrated complete prophylactic and potent therapeutic efficacy in a rhesus macaque disease model. Prophylactic and therapeutic countermeasure intervention of SARS-CoV-2 using JMB2002 would likely slow down the transmission of currently emerged SARS-CoV-2 variants and result in more efficient control of the COVID-19 pandemic.Competing Interest StatementC. G., X. C., Z. W., P. L., X. L., L. G., F. J., L. Y., N. L., G. J., J. Z., L. Y., M. S., T. H., Y. L., W. L., G. L., C. Y., Y. W., K. X., Z. X., J. X., X. H., X. C., Z. P., X. W., H. G., H. L., and S. D. were employed by Shanghai Jemincare Pharmaceuticals Co., Ltd. All other authors declared no competing interests.